

Figure 1: Mean famotidine plasma concentrations for the two formulations as a function of time.



## **Formulation**



APPEARS THIS WAY ON ORIGINAL

Table 3: Composition of the proposed gelcap formulation.




Figure 2: Dissolution profiles of the three stability batches. C-674-1B is the batch used in the bioequivalence study.

